Bank of America (BofA) recently released the findings of an employer survey that found that the pharmacy benefit marketplace is highly competitive, confirmed that surveyed employers believe their pharmacy benefit company is transparent to them, and underscored the savings, flexibility,
(Washington, D.C.) — A new academic analysis, “Independent Pharmacies in the U.S. are More on the Rise than on the Decline,” sets the record straight on the health of independent pharmacies in the U.S. by showing the overall number of
During the Energy and Commerce Health Subcommittee hearing on “The Fiscal Year 2021 HHS Budget and Oversight of the Coronavirus Outbreak” several inaccurate remarks were made on pharmacy direct and indirect remuneration (DIR). What is Pharmacy DIR? Pharmacy benefit managers
In case you missed it, the Pharmaceutical Care Management Association (PCMA) released a new Rx Research Corner blog, by Vice President of Research Amanda Frost, that quantifies what a world without pharmacy benefit companies would look like for employers and
(Washington, D.C.) — As prescription drug spending is poised to reach as much as $5 trillion during the next decade, new data find that pharmacy benefit managers’ (PBMs’) proven cost savings and patient care management tools should reduce prescription drug
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former White House domestic policy adviser,
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
Last week, the U.S. House Ways and Means Committee Health Subcommittee held a hearing on “Why Health Care is Unaffordable: Anticompetitive and Consolidated Markets.” During the hearing, Congressman Kevin Hern (R-OK) shared that, as a former business owner, he was
A recent white paper (“The Association Between Drug Rebates and List Prices”) narrowly suggests an association between list prices for brand drugs and the rebate practices of pharmacy benefit managers (PBMs) and insurers, despite an underlying methodology that is notably broader
Named a 2022 Top Lobbyist by The Hill, Lebens Will Lead PCMA’s Federal Lobbying Team (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is today announcing Lucia Lebens as Senior Vice President of Federal Affairs and Political Strategy at
©2024 PCMA. All Rights Reserved.
